anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Pharmacotherapy for trichotillomania
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Trichotillomania
Provide patient population that should be included in the study
Sulthiame monotherapy for epilepsy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Epilepsy 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Treatments for seizures in catamenial (menstrual‐related) epilepsy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Menstrual Epilepsy
Provide patient population that should be included in the study
Non‐pharmacological interventions for stuttering in children six years and younger
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Stuttering 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Obsessive-compulsive Disorder 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Autism Spectrum Disorder 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin D supplementation for chronic liver diseases in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Chronic Liver Disease 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Cystic Fibrosis 6. Young Adult 19-24 years 7. Birth to 1 mo 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Heliox for croup in children
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Laryngotracheobronchitis 4. Birth to 1 mo 5. Croup
Provide patient population that should be included in the study
Chloral hydrate as a sedating agent for neurodiagnostic procedures in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Neurodevelopmental Disorder 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Direct composite resin fillings versus amalgam fillings for permanent posterior teeth
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Dental Caries 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuous versus bolus intermittent intragastric tube feeding for preterm and low birth weight infants with gastro‐oesophageal reflux disease
1. Gastroesophageal Reflux Disease 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Push versus gravity for intermittent bolus gavage tube feeding of preterm and low birth weight infants
1. Enteral nutrition 2. Birth to 1 mo 3. Low Birth Weight Infant 4. Preterm Infant 5. Tube Feeding
Provide patient population that should be included in the study
Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cystic Fibrosis 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Schedules for home visits in the early postpartum period
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Mother Delivered 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioid treatment for opioid withdrawal in newborn infants
1. Neonate 2. Birth to 1 mo 3. Neonatal Aspiration Syndromes
Provide patient population that should be included in the study
Sunlight for the prevention and treatment of hyperbilirubinemia in term and late preterm neonates
1. Hyperbilirubinemia 2. Term Pregnancy 3. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Bisphosphonate use in children with cerebral palsy
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Cerebral Palsy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Ivermectin treatment in humans for reducing malaria transmission
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Altered dietary salt intake for people with chronic kidney disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Kidney Disease 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuous nasogastric milk feeding versus intermittent bolus milk feeding for preterm infants less than 1500 grams
1. Intravenous Feeding Of Patient 2. Birth to 1 mo 3. Very Low Birth Weight Infant
Provide patient population that should be included in the study
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Drug Resistant Epilepsy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic drug management for febrile seizures in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Febrile Convulsion
Provide patient population that should be included in the study
Oral antibiotics for chronic blepharitis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Blepharitis 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical azole treatments for otomycosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Otomycosis 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
New generation antidepressants for depression in children and adolescents: a network meta‐analysis
1. Child 6-12 years 2. Major depressive disorder 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets to prevent malaria in Africa
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Prevention Of Malaria 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Internet‐based cognitive and behavioural therapies for post‐traumatic stress disorder (PTSD) in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Posttraumatic Stress Disorder 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Sedatives for opioid withdrawal in newborn infants
1. Neonate 2. Birth to 1 mo 3. Neonatal Aspiration Syndromes
Provide patient population that should be included in the study
Antibiotic regimens for early‐onset neonatal sepsis
1. Birth to 1 mo 2. Perinatal Sepsis
Provide patient population that should be included in the study
Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Gastroesophageal Reflux Disease 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Asthma
Provide patient population that should be included in the study
Rubber dam isolation for restorative treatment in dental patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Dental Caries 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome
1. Birth to 1 mo 2. Neonatal Respiratory Distress Syndrome 3. Preterm Infant
Provide patient population that should be included in the study
Topical emollient for preventing infection in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Paying for performance to improve the delivery of health interventions in low‐ and middle‐income countries
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Healthcare services 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epileptic Seizure 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Infection Of Bloodstream 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug therapies for reducing gastric acidity in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Abnormal Gastric Acidity 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Cough augmentation techniques for people with chronic neuromuscular disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Respiratory Disorders 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Neuromuscular Disorder 10. Chronic Disease 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antidepressants for people with epilepsy and depression
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Depression 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Anti‐seizure medications for Lennox‐Gastaut syndrome
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Lennox-gastaut Syndrome 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Circumcision 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Lung recruitment manoeuvres for reducing mortality and respiratory morbidity in mechanically ventilated neonates
1. Birth to 1 mo 2. Mechanical ventilation
Provide patient population that should be included in the study
Dornase alfa for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Lung disorder 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Opioids for newborn infants receiving mechanical ventilation
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Mechanical ventilation
Provide patient population that should be included in the study
Zinc supplementation for improving pregnancy and infant outcome
1. Adult 19-44 years 2. First Trimester Pregnancy 3. Middle Aged 45-64 years 4. Second Trimester Pregnancy 5. Young Adult 19-24 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates
1. Infant 1 to 23 mo 2. Birth to 1 mo 3. Low Birth Weight Infant 4. Preterm Infant
Provide patient population that should be included in the study
High versus standard volume enteral feeds to promote growth in preterm or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Timing of dornase alfa inhalation for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for self‐harm in children and adolescents
1. Child 6-12 years 2. Self-harm 3. Adolescent 13-18 years
Provide patient population that should be included in the study
High‐flow nasal cannulae for respiratory support in adult intensive care patients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Critical Illness 6. Mechanical ventilation 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Type 1 Diabetes Mellitus 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for bacterial folliculitis and boils (furuncles and carbuncles)
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Bacterial Folliculitis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Carbuncle/boil
Provide patient population that should be included in the study
Antibiotics to prevent complications following tooth extractions
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Tooth Extraction 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Patient and lay carer education for preventing pressure ulceration in at‐risk populations
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Fluid restriction in the management of transient tachypnea of the newborn
1. Transitory Tachypnea Of Newborn 2. Neonate 3. Birth to 1 mo
Provide patient population that should be included in the study
The effectiveness and adverse effects of D‐cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Autism Spectrum Disorder 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical versus systemic antibiotics for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Suppurative Otitis Media
Provide patient population that should be included in the study
Salbutamol for transient tachypnea of the newborn
1. Transitory Tachypnea Of Newborn 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Preterm Infant
Provide patient population that should be included in the study
Systemic antibiotics for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Otitis Media
Provide patient population that should be included in the study
Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Kidney Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Beta‐blockers versus placebo or no intervention for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Surgical interventions for the early management of Bell's palsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Bell's Palsy 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Effect of atorvastatin on testosterone levels
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Metabolic Syndrome 5. Infant 1 to 23 mo 6. Hyperlipidemia 7. Dyslipidemia 8. Cardiovascular disease 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Adult 19-44 years 12. Middle Aged 45-64 years 13. Chronic kidney failure 14. Type 2 Diabetes Mellitus 15. Young Adult 19-24 years 16. Birth to 1 mo 17. Chronic Disease Of Cardiovascular System 18. Polycystic Ovarian Syndrome 19. Hypertensive disorder 20. Healthy
Provide patient population that should be included in the study
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Absence Seizure 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO‐defined non‐severe pneumonia and wheeze
1. Pneumonia 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
Interventions for treating iron deficiency anaemia in inflammatory bowel disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Inflammatory Bowel Disease 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Iron Deficiency Anemia
Provide patient population that should be included in the study
Indomethacin for symptomatic patent ductus arteriosus in preterm infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant 4. Patent Ductus Arteriosus
Provide patient population that should be included in the study
Early full enteral feeding for preterm or low birth weight infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Oral hygiene care for critically ill patients to prevent ventilator‐associated pneumonia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Mechanical ventilation 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Cancer
Provide patient population that should be included in the study
Respiratory muscle training for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Magnesium sulphate for treating acute bronchiolitis in children up to two years of age
1. Acute Bronchiolitis 2. Infant 1 to 23 mo
Provide patient population that should be included in the study
Effects of oral vitamin D supplementation on linear growth and other health outcomes among children under five years of age
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo
Provide patient population that should be included in the study
Vitamin D supplementation for term breastfed infants to prevent vitamin D deficiency and improve bone health
1. Infant 1 to 23 mo 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Breast Fed
Provide patient population that should be included in the study
Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant 4. Patent Ductus Arteriosus
Provide patient population that should be included in the study
N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Acute Hepatic Failure 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to increase patient and family involvement in escalation of care for acute life‐threatening illness in community health and hospital settings
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Family Support 5. Young Adult 19-24 years 6. Caregiver 7. Adjustment To Life Threatening Illness 8. Critical Illness 9. Aged 65-79 years
Provide patient population that should be included in the study
Probiotics for treating acute infectious diarrhoea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Acute Diarrhea 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pneumococcal conjugate vaccines for preventing acute otitis media in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo
Provide patient population that should be included in the study
Individualized versus standard diet fortification for growth and development in preterm infants receiving human milk
1. Birth to 1 mo 2. Low Birth Weight Infant 3. Preterm Infant
Provide patient population that should be included in the study
Comparison of different protein concentrations of human milk fortifier for promoting growth and neurological development in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Cerebral Palsy 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive behavioural therapy for anxiety disorders in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Anxiety Disorder 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Band ligation versus sclerotherapy for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Chronic Liver Disease 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Portal Vein Thrombosis 7. Adolescent 13-18 years 8. Esophageal Varices
Provide patient population that should be included in the study
Rufinamide add‐on therapy for drug‐resistant epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Drug Resistant Epilepsy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatment for continuous spike‐wave during slow wave sleep syndrome and Landau‐Kleffner Syndrome
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Epileptic encephalopathy 4. Infant 1 to 23 mo 5. Epilepsy With Continuous Spike Wave During Slow-wave Sleep 6. Birth to 1 mo
Provide patient population that should be included in the study
Pit and fissure sealants versus fluoride varnishes for preventing dental decay in the permanent teeth of children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Young Adult 19-24 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Obstructive Sleep Apnea Syndrome 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Specialised early intervention teams for recent‐onset psychosis
1. Psychosis 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Specialised early intervention teams (extended time) for recent‐onset psychosis
1. Psychosis 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Physical activity interventions for people with congenital heart disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Congenital Heart Disease 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Virtual reality distraction for acute pain in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Acute Pain 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Drug treatments for managing cystic fibrosis‐related diabetes
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Diabetes Mellitus Associated With Cystic Fibrosis 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Early versus delayed continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Birth to 1 mo 2. Neonatal Respiratory Distress Syndrome 3. Preterm Infant
Provide patient population that should be included in the study
Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants
1. Birth to 1 mo 2. Respiratory Failure 3. Preterm Infant
Provide patient population that should be included in the study
Interventions to reduce contaminated aerosols produced during dental procedures for preventing infectious diseases
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Aerosol generating procedure 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Dental procedures 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Cardiopulmonary Bypass 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Household interventions for secondary prevention of domestic lead exposure in children
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Adult 19-44 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Exposure to lead 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Branched‐chain amino acid supplementation for improving growth and development in term and preterm neonates
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Pine bark (Pinus spp.) extract for treating chronic disorders
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Chronic Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Protein supplementation of human milk for promoting growth in preterm infants
1. Birth to 1 mo 2. Hospitalization 3. Preterm Infant
Provide patient population that should be included in the study
Interventions for preventing ophthalmia neonatorum
1. Neonatal Conjunctivitis 2. Birth to 1 mo 3. Ophthalmia neonatorum
Provide patient population that should be included in the study
Aural toilet (ear cleaning) for chronic suppurative otitis media
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Ear Drum Perforation 6. Chronic Disease Of Ear 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Otorrhea 10. Adult 19-44 years 11. Middle Aged 45-64 years 12. Young Adult 19-24 years 13. Birth to 1 mo 14. Chronic Suppurative Otitis Media
Provide patient population that should be included in the study
Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review
1. COVID-19
Provide patient population that should be included in the study
Systemic treatments for eczema: a network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Atopic Dermatitis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Eczema 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Carbohydrate supplementation of human milk to promote growth in preterm infants
1. Enteral nutrition 2. Birth to 1 mo 3. Preterm Infant
Provide patient population that should be included in the study
Psychological and social interventions for the prevention of mental disorders in people living in low‐ and middle‐income countries affected by humanitarian crises
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Low Middle Income 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Humanitarian Crisis 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological treatments for people with epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin E supplementation in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Hydrosurgical debridement versus conventional surgical debridement for acute partial‐thickness burns
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Second-degree burn 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacotherapy for hyperuricaemia in hypertensive patients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Prehypertension 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Hyperuricemia 10. Middle Aged 45-64 years 11. Young Adult 19-24 years 12. Birth to 1 mo 13. Essential Hypertension
Provide patient population that should be included in the study
Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Ulcerative Colitis In Remission 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Surgical interventions for primary congenital glaucoma
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Birth to 1 mo 4. Congenital Glaucoma
Provide patient population that should be included in the study
Interventions for American cutaneous and mucocutaneous leishmaniasis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. American Cutaneous/mucocutaneous Leishmaniasis 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fat supplementation of human milk for promoting growth in preterm infants
1. Enteral nutrition 2. Birth to 1 mo 3. Hospitalization 4. Preterm Infant
Provide patient population that should be included in the study
Antibiotic therapy for pelvic inflammatory disease
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Pid Pelvic Inflammatory Disease 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
1. Cerebral Hypoxia-Ischemia 2. Term infant (37-41 weeks) 3. Birth to 1 mo 4. Late Preterm Infant (34-36 weeks)
Provide patient population that should be included in the study
Intravenous immunoglobulin for presumed viral myocarditis in children and adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Acute Myocarditis 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Left Ventricular Ejection Fraction 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Vivax Malaria 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Digital contact tracing technologies in epidemics: a rapid review
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Mobility management to prevent, reduce, or delay driving a car in teenagers
1. Adolescence 2. Young Adult 19-24 years 3. Adolescent 13-18 years
Provide patient population that should be included in the study
Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Polycystic Ovarian Syndrome 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral non‐steroidal anti‐inflammatory drugs versus other oral analgesic agents for acute soft tissue injury
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Soft Tissue Injury
Provide patient population that should be included in the study
Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Ulcerative Colitis 4. Young Adult 19-24 years 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Pancreatic enzyme replacement therapy for people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Perioperative antibiotics for preventing post‐surgical site infections in solid organ transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Solid Organ Transplant 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Kidney transplant 8. Young Adult 19-24 years 9. Diabetes Mellitus 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early fortification of human milk versus late fortification to promote growth in preterm infants
1. Birth to 1 mo 2. Preterm Infant
Provide patient population that should be included in the study
Topical treatment for facial burns
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Burn Of Face 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Education of family members to support weaning to solids and nutrition in later infancy in term‐born infants
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Term infant (37-41 weeks) 4. Parent 5. Young Adult 19-24 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta‐blockers for congestive heart failure in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Congestive Heart Failure 4. Infant 1 to 23 mo 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Workplace pedometer interventions for increasing physical activity
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Employee 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for the management of obesity in people with bipolar disorder
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Obesity 5. Middle Aged 45-64 years 6. Bipolar Disorder 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Statins for asthma
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Asthma
Provide patient population that should be included in the study
Head midline position for preventing the occurrence or extension of germinal matrix‐intraventricular haemorrhage in preterm infants
1. Very Preterm Infant (28-31 weeks) 2. Intraventricular Hemorrhage 3. Germinal Matrix Hemorrhage 4. Birth to 1 mo 5. Intensive Care
Provide patient population that should be included in the study
Psychological interventions for psychosis in adolescents
1. Psychosis 2. Adolescent 13-18 years
Provide patient population that should be included in the study
Lamotrigine add‐on therapy for drug‐resistant generalised tonic‐clonic seizures
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Drug Resistant Epilepsy 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Generalized Epilepsy 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Use of reflective materials during phototherapy for newborn infants with unconjugated hyperbilirubinaemia
1. Term infant (37-41 weeks) 2. Birth to 1 mo 3. Preterm Infant 4. Unconjugated Hyperbilirubinemia
Provide patient population that should be included in the study
Potassium binders for chronic hyperkalaemia in people with chronic kidney disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Chronic Kidney Disease 8. Aged 65-79 years 9. Adolescent 13-18 years 10. Chronic Hyperkalemia
Provide patient population that should be included in the study
Ketogenic diets for drug‐resistant epilepsy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Epilepsy 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Cognitive‐behavioural therapy (CBT) interventions for young people aged 10 to 18 with harmful sexual behaviour
1. Child 6-12 years 2. Harmful sexual behaviour 3. Sexual Offending Behavior 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Pitavastatin for lowering lipids
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Metabolic Syndrome 4. Middle Aged 45-64 years 5. Chronic kidney failure 6. Type 2 Diabetes Mellitus 7. Young Adult 19-24 years 8. Cardiovascular disease 9. Aged 65-79 years 10. Hypertensive disorder
Provide patient population that should be included in the study
Low molecular weight heparin for prevention of central venous catheter‐related thrombosis in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Central Venous Catheter In Situ 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Ventriculo‐peritoneal shunting devices for hydrocephalus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Hydrocephalus 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Cystic Fibrosis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Infection due to Pseudomonas Aeruginosa 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Non-tuberculous Mycobacterial Pneumonia 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin K supplementation for cystic fibrosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Cystic Fibrosis 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Multi‐nutrient fortification of human milk for preterm infants
1. Enteral nutrition 2. Birth to 1 mo 3. Low Birth Weight Infant 4. Preterm Infant